Global
Breaching the Great Wall: Major Changes for Pharma in China
Behind the vaulting growth statistics that make China the centerfold in Big Pharma’s global playbook is a sobering fact: registering a new drug for local sale is still a slow, dimly lit game of chance. But, with a revision of China’s basic drug approval law now underway, a multinational team of experts is proposing major changes to make the country a world class player in innovation ...Read more
Patient Outcomes
PCORI Explains Slow Take-Up of Comparative Effectiveness Research
Last week, the federal government’s Patient Centered Outcomes Research Institute (PCORI) unveiled a survey revealing that both patients and clinicians want in health research to focus on one thing: improving outcomes. But while patients and physicians value Comparative Effectiveness Research (CER), most are not familiar with what it entails ...Read more
Pricing
Battle Escalates Over 340B Drug Pricing Program
What was once an obscure federal policy for providing low-cost drugs to safety-net hospitals has grown into a program that requires extensive discounting to one-third of the nation’s hospitals and health clinics. Pharma companies are pushing back, heightening tensions between “covered entities” that qualify for greatly reduced prices on medicines under 340B — and manufacturers that see the discounts making a big dent in US revenues. Jill Wechsler reports ...Read more
SciVigilance – Pharmacovigilance in a box
SciVigilance provides the powerful combination of streamlined processes, domain expertise and robust technology that integrates disparate data and enables the seamless flow, collection processing and analysis of data. SciVigilance delivers significant time and cost savings, efficiency and compliance gains, all while delivering the highest quality outcomes. Read More
Politics
Messaging in Healthcare: Making Sound and Fury Signify Something
Recently, there was a bit of a dust-up over whether it was appropriate for the Secretary of Health and Human Services (HHS) to engage the National Football League (NFL) to help HHS with the process of drumming-up enrollment for health insurance exchanges. In the end, the NFL and other sports leagues decided they were not going to be involved, fearing the appearance of taking political sides. The HHS is better off with this outcome, writes Les Funtleyder ...Read more
Digital Pharma
Social Media’s Not That Scary… Now for Social Business
Pharma marketers may have finally conquered their fear of social media. But are companies prepared now to become ‘social businesses’ asks Peter Houston ...Read more
New eBook
The Best of the Successful Product Manager's Handbook Volume II
In the second volume of this four-volume set from the pages of Pharmaceutical Executive,
learn to think outside the box to meet both timeless and newly emerging obstacles to success ...Read more
|
